

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Nathalie Norais

Serial No.: 10/535,168

Confirmation No.: 5751

Filing Date: June 29, 2006

Group Art Unit: 1645

For: Unexpected Surface Proteins in Meningococcus

Via EFS-Web  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

**INFORMATION DISCLOSURE STATEMENT**

Pursuant to 37 C.F.R. §§ 1.56 and in accordance with 37 C.F.R. §§ 1.97 and 1.98, information relating to the above-identified application is hereby disclosed, the Examiner in charge of the above-identified application is requested to consider and make of record the references listed on Form PTO/SB/08, submitted herewith.

Inclusion of the information submitted herewith is not to be construed as an admission that the information is material as that term is defined in 37 C.F.R. § 1.56(b).

In accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

**This Information Disclosure Statement is being filed:**

- within three months of the filing date of the patent application.
- within three months of the date of entry into the national stage as set forth in 37 C.F.R. § 1.491 of the international application.
- before the mailing date of a first Office Action on the merits.

- after the mailing date of a first Office Action on the merits, but before the mailing date of a Final Office Action under 37 C.F.R. § 1.116 or a Notice of Allowance under 37 C.F.R. § 1.311, and accordingly is accompanied by:
  - the Statement under 37 C.F.R. § 1.97(e) (see "Statement" below);

or
  - the Fee of \$180.00 set forth in 37 C.F.R. § 1.17(p); or
  - No fee is owed by the applicant(s).
- In accordance with 37 C.F.R. § 1.129(a), this Information Disclosure Statement is being filed in connection with  the first or  second After Final Submission, and accordingly is accompanied by the Statement under 37 C.F.R. § 1.97(e) (see "Statement" below) and the fee of \$180.00 as set forth in 37 C.F.R. § 1.17(p), is attached.
- after the mailing date of a Final Office Action under 37 C.F.R. § 1.116 or a Notice of Allowance under 37 C.F.R. § 1.311, but before the payment of the Issue Fee, and accordingly is accompanied by the Statement under 37 C.F.R. § 1.97(e), (see "Statement," and "Fees" below).
- Copies of each of the non-U.S. Patent documents listed on the attached Form PTO/SB/08, are enclosed herewith.

**EXCEPT THAT:**

- In view of the voluminous nature of reference @@, and the likelihood that this reference is available to the Examiner, copies are not enclosed herewith.
- In accordance with 37 C.F.R. § 1.98(d), copies of the following references listed on the attached Form PTO/SB/08 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C. § 120 have been made in the instant application.

If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

**Concise Explanation Requirement**

The "concise explanation" requirement (non-English references) for reference B2 under 37 C.F.R. § 1.98(a)(3) is satisfied by:

- the explanation provided on the attached sheet.
- the explanation provided in the Specification.
- submission of the enclosed International Search Report.
- submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action..
- the English-language abstract provided on the cover page of B2.

**Statement under 37 C.F.R. § 1.97(e)**

The undersigned attorney hereby states that each item contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Information Disclosure Statement.

**Fees**

No Fee is owed by the applicant(s).

The Information Disclosure Statement Fee of \$180.00 under 37 C.F.R. § 1.17(p) is enclosed herewith.

**Method of Payment of Fees**

Attached is a check in the amount of \$\_\_\_\_\_ This form is submitted in duplicate.

- Charge Deposit Account No. 03-1664 in the amount of \$180.00. This form is submitted in duplicate.
- Please charge any deficiency or credit any overpayment to Deposit Account 03-1664.
- No fee or Statement is required under 37 C.F.R. § 1.97(b).

Respectfully submitted,

Dated: 1/7/04

By: 

Amy Hessler  
Registration No. 50,310

NOVARTIS VACCINES AND DIAGNOSTICS, INC.  
Intellectual Property Dept. - X100B  
4560 Horton Street  
Emeryville, CA 94608-2916  
Telephone: (510) 923-3833  
Facsimile: (510) 655-3542